The healthcare sector is currently witnessing a paradigm shift of historical magnitude, transitioning from a reactive, hospital-centric model to a proactive, continuous, and patient-centric ecosystem. At the heart of this transformation lies the "Internet of Health" (IoH), a term that describes the convergence of consumer electronics, clinical diagnostics and cloud computing. Unlike the broader Internet of Things (IoT), which encompasses everything from smart refrigerators to

Join Future Health Intelligence for an end of year market insight webinar to review the key changes that have shaped 2025 and to gain insights into the key trends that will drive the NHS and UK health IT market in 2026 and beyond, identifying the key emerging market opportunities from the three left shifts set out in the NHS 10-year Plan: Fit for the Future.   

Updates for the week of November 24–28, 2025, are headlined by a major intervention from WHO Europe on AI safety, fresh capital for Nordic oncology innovation, and significant new regulatory guidance from the UK's MHRA. Updates from the week of November 24–28, 2025, highlight a significant shift in the regulatory landscape for European MedTech, alongside major investment news and post-conference analysis from MEDICA 2025.

In terms of volume and relevance to the mid-market founder, the demographic most prevalent in the European innovation ecosystem, firms like Rothschild & Co, Houlihan Lokey and highly specialised boutiques like Nelson Advisors, Arma Partners and Clipperton have emerged as the primary engines of liquidity.

Key developments in the European MedTech sector for the week of November 21st 2025, have been dominated by major regulatory shifts regarding AI, significant capital injections, and activity surrounding two major industry conferences. While the broader medical device sector is focused on hardware delays, the HealthTech conversation this week shifted sharply toward data access and AI liability.

The evolution of the Quantified Self (QS) movement from 2010 to 2025 represents one of the most profound shifts in the history of personal health, technology, and sociology. What began as a fringe subculture of "bio-hackers" and data enthusiasts in the San Francisco Bay Area has metastasised into a global infrastructure for predictive healthcare, underpinning a multi-billion-dollar market for wearable technology, remote patient monitoring (RPM), and personalised medicine.

The European Healthcare Information Technology (HCIT) and Artificial Intelligence (AI) mergers and acquisitions landscape is currently navigating a period of profound structural transformation. Following the exuberant valuation cycles of 2020-2021 and the subsequent correction, the 2024-2025 period is defined by a "flight to quality" and a rigorous emphasis on clinical utility over theoretical potential. For Venture Capital (VC) funds operating across the continent, the s

Defining the 'Board to Ward' Continuum: Phases and Core Stakeholders. The trajectory of health technology, encompassing MedTech, diagnostics and digital health tools, from conceptualisation to routine clinical utilisation in the UK is defined by a multi-stage pathway involving distinct regulatory, value assessment and commissioning checkpoints. This journey is broken down into five interwoven phases: Idea Creation, Development, Evidence Generation, Commissioning and Adoption

The European HealthTech market, encompassing Healthcare IT and Artificial Intelligence (AI), presents a robust and timely opportunity for specialised Private Equity (PE) deployment in 2026. Following a period defined by market correction and post-COVID-19 volatility, the sector is experiencing a strategic rebound driven by demographic pressures, mandatory regulatory shifts and the transition from fragmented point solutions to scalable, proven business models.

The United Kingdom has established an ambitious policy framework, driven by the National AI Strategy and the dedicated work of the NHS AI Lab, to become a global leader in the safe, ethical, and responsible deployment of Artificial Intelligence (AI) within its healthcare ecosystem. This ambition, overseen by the Office for Artificial Intelligence (a joint BEIS-DCMS unit), seeks to drive innovation that benefits all citizens. However, a significant gap persists between aspirat

Digital Health/HealthTech is currently driving much of the innovation in European healthcare.Building on the developments from this week, here are the major highlights specifically within the European HealthTech sector..

OpenAI, having established market dominance with its foundational Large Language Model (LLM) infrastructure, is actively exploring a major expansion into the high-value, high-risk consumer health sector.This strategic pivot moves the company aggressively beyond its core chatbot and API offerings toward developing industry-specific software. The central focus of this initiative is the enablement of Personal Health Records (PHR) through two anticipated core products: a generati

The high street wellness phenomenon represents a fundamental structural transformation of England’s town and city centres, shifting the core economic function from cyclical, transactional retail toward resilient, service-based, and experience-led health and wellbeing offerings. This transition is not merely cosmetic; it is driven by powerful macroeconomic forces, notably the structural resilience of the self-pay health consumer and targeted government intervention aimed at hi

Nelson Advisors Partner Lloyd Price has been invited to join the 'Building the case for Goldilocks Medicine' Debate at the Havas Leaders in Health Summit 2025. The overarching question driving the Summit is: "Can Precision Breakthroughs, Regulatory Revolution & AI (Re)Humanise Healthcare?" The goal is to explore how to "Make medicine personable again."

The Mergers and Acquisitions (M&A) landscape for HealthTech and MedTech is poised for a significant strategic acceleration in 2026, transitioning from cautious, volume-driven dealmaking witnessed in previous years to high-value, transformative transactions. This resurgence is supported by stabilising credit markets, renewed corporate confidence, and a critical, anticipated pivot in US. antitrust enforcement policy, which is expected to facilitate large, strategic combinat